disseminated prostate cancerhormone therapycontinuous regimenintermittent regimenраспространенный рак предстательной железыгормонотерапияпостоянный режиминтермиттирующий режим1.1. Матвеев Б.П., Бухаркин Б.В., Матвеев В.Б. Рак предстательной железы. М., 1999.Матвеев Б.П., Бухаркин Б.В., Матвеев В.Б. Рак предстательной железы. М., 1999.2.2. Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80.Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80.3.3. Pether M., Goldenberg S.L. Intermittent androgen suppression. BJU Int 2004; 93(3):258–61.Pether M., Goldenberg S.L. Intermittent androgen suppression. BJU Int 2004; 93(3):258–61.4.4. Hussain M., Tangen C.M., Higano C. et al; Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984–90.Hussain M., Tangen C.M., Higano C. et al; Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984–90.5.5. Lane T.M., Ansell W., Farrugia D. et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004;73(2):117–22.Lane T.M., Ansell W., Farrugia D. et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004;73(2):117–22.6.6. de Leval J., Boca P., Yousef E. et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1(3):163–71.de Leval J., Boca P., Yousef E. et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1(3):163–71.7.7. Tunn U.W., Canepa G., Hillger H., Fuchs W. Intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy – final results of a European randomized prospective phase-III clinical trial, AUO study AP 06/95, EC 507. American Urological Association 2007; abstr 600.Tunn U.W., Canepa G., Hillger H., Fuchs W. Intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy – final results of a European randomized prospective phase-III clinical trial, AUO study AP 06/95, EC 507. American Urological Association 2007; abstr 600.8.8. Miller K., Steiner U., Lingnau A. et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 2007;Part 1;25(18);abstr 5015.Miller K., Steiner U., Lingnau A. et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 2007;Part 1;25(18);abstr 5015.9.9. Irani J., Celhay O., Hubert J. et al; Association for Research in Urological Oncology. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur Urol 2008;54(2):382–91.Irani J., Celhay O., Hubert J. et al; Association for Research in Urological Oncology. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur Urol 2008;54(2):382–91.10.10. da Silva F.E., Bono A.V., Whelan P. et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase III study of the South European Uroncological Group. Eur Urol 2009;55(6):1269–77.da Silva F.E., Bono A.V., Whelan P. et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase III study of the South European Uroncological Group. Eur Urol 2009;55(6):1269–77.11.11. Bruchovsky N., Rennie P.S., Coldman A.J. et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50(8):2275–82.Bruchovsky N., Rennie P.S., Coldman A.J. et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50(8):2275–82.